190 related articles for article (PubMed ID: 21997981)
1. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents.
Goodwin MD; Dobson JE; Sirlin CB; Lim BG; Stella DL
Radiographics; 2011 Oct; 31(6):1547-68. PubMed ID: 21997981
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis.
Fowler KJ; Brown JJ; Narra VR
Hepatology; 2011 Dec; 54(6):2227-37. PubMed ID: 21932400
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
[TBL] [Abstract][Full Text] [Related]
4. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte-specific magnetic resonance imaging contrast agents.
Fidler J; Hough D
Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
[No Abstract] [Full Text] [Related]
6. Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight.
Pastor CM
Radiology; 2010 Nov; 257(2):589. PubMed ID: 20959554
[No Abstract] [Full Text] [Related]
7. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
Burke C; Alexander Grant L; Goh V; Griffin N
Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
[TBL] [Abstract][Full Text] [Related]
9. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine.
Pediconi F; Catalano C; Padula S; Roselli A; Dominelli V; Cagioli S; Kirchin MA; Pirovano G; Passariello R
AJR Am J Roentgenol; 2008 Nov; 191(5):1339-46. PubMed ID: 18941066
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
Feuerlein S; Gupta RT; Boll DT; Merkle EM
Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
[TBL] [Abstract][Full Text] [Related]
11. Half-dose gadobenate dimeglumine versus standard-dose gadodiamide in dynamic magnetic resonance imaging of non-cirrhotic livers: a retrospective intra-individual crossover comparison.
Homayoon B; Diwakar H; Strovski E; Bakshi D; Harris AC; Thoeni RF; Chang SD
Abdom Imaging; 2014 Oct; 39(5):955-62. PubMed ID: 24676875
[TBL] [Abstract][Full Text] [Related]
12. A Pictorial Review of Hepatobiliary Magnetic Resonance Imaging With Hepatocyte-Specific Contrast Agents: Uses, Findings, and Pitfalls of Gadoxetate Disodium and Gadobenate Dimeglumine.
Scali EP; Walshe T; Tiwari HA; Harris AC; Chang SD
Can Assoc Radiol J; 2017 Aug; 68(3):293-307. PubMed ID: 28583364
[TBL] [Abstract][Full Text] [Related]
13. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Gd-Bz-TTDA, Gd-EOB-DTPA, and Gd-BOPTA for dynamic MR imaging of the liver in rat models.
Jaw TS; Chen SH; Wang YM; Hsu JS; Kuo YT; Chiu YY; Tsai KB; Hsieh TJ; Liu GC
Kaohsiung J Med Sci; 2012 Mar; 28(3):130-7. PubMed ID: 22385605
[TBL] [Abstract][Full Text] [Related]
15. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
Giovagnoni A; Paci E
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
[TBL] [Abstract][Full Text] [Related]
17. Gadoxetic acid disodium-enhanced magnetic resonance imaging for biliary and vascular evaluations in preoperative living liver donors: comparison with gadobenate dimeglumine-enhanced MRI.
Lee MS; Lee JY; Kim SH; Park HS; Kim SH; Lee JM; Han JK; Choi BI
J Magn Reson Imaging; 2011 Jan; 33(1):149-59. PubMed ID: 21182133
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions.
Pirovano G; Vanzulli A; Marti-Bonmati L; Grazioli L; Manfredi R; Greco A; Holzknecht N; Daldrup-Link HE; Rummeny E; Hamm B; Arneson V; Imperatori L; Kirchin MA; Spinazzi A
AJR Am J Roentgenol; 2000 Oct; 175(4):1111-20. PubMed ID: 11000175
[TBL] [Abstract][Full Text] [Related]
19. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
Thomeer MG; Willemssen FE; Biermann KK; El Addouli H; de Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
[TBL] [Abstract][Full Text] [Related]
20. Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging.
Hamm B; Thoeni RF; Gould RG; Bernardino ME; Lüning M; Saini S; Mahfouz AE; Taupitz M; Wolf KJ
Radiology; 1994 Feb; 190(2):417-23. PubMed ID: 8284392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]